title: Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori.
abstract: Various approaches have been proposed to overcome the unpleasant side-effects associated with antibiotic treatment for Helicobacter pylori. The limited effectiveness of such approaches has forced researchers to consider alternative strategies to eliminate H. pylori infection. The plant alkaloid berberine is known to significantly reduce proliferation of H. pylori. To localize berberine to the site of H. pylori infection, this study developed a novel nanoparticle berberine carrier with a heparin shell. Analysis of a simulated gastrointestinal medium indicated that the proposed in vitro drug carrier system effectively controlled the release of berberine, which interacted specifically with the intercellular space at the site of H. pylori infection. Furthermore, the prepared nanoparticles significantly increased the suppressive effect of berberine on H. pylori growth while efficiently reducing cytotoxic effects in H. pylori-infected cells.
authors.affiliation: School of Chinese Medicine, China Medical University and Department of Traditional Chinese Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.
authors.forename: Chiung-Hung
authors.initials: CH
authors.lastname: Chang
authors.forename: Wen-Ying
authors.initials: WY
authors.lastname: Huang
authors.forename: Chih-Ho
authors.initials: CH
authors.lastname: Lai
authors.forename: Yuan-Man
authors.initials: YM
authors.lastname: Hsu
authors.forename: Yi-Hsing
authors.initials: YH
authors.lastname: Yao
authors.forename: Ting-Yu
authors.initials: TY
authors.lastname: Chen
authors.forename: Jing-Yan
authors.initials: JY
authors.lastname: Wu
authors.forename: Shu-Fen
authors.initials: SF
authors.lastname: Peng
authors.forename: Yu-Hsin
authors.initials: YH
authors.lastname: Lin
mesh_terms: D001599:Berberine / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D048271:Chitosan / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems; D005453:Fluorescence; D016480:Helicobacter pylori / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D018613:Microscopy, Confocal; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D010316:Particle Size; D012996:Solutions; D021241:Spectrometry, Mass, Electrospray Ionization; D017550:Spectroscopy, Fourier Transform Infrared; D055672:Static Electricity
chemical_list: D012996:Solutions; D001599:Berberine; D006493:Heparin; D048271:Chitosan